Back to search
FDAFDA · Food and drugs·Recall number D-1439-2014

Velivet (desogestrel and ethinyl estradiol tablets - triphasic regimen), 0.1 mg/0.025 mg; 0.125 mg/0.025 mg; 0.15 mg/0.025 mg, 3 Dispensers x 28 Tablets, Barr Laboratories, Inc., Pomona, NY NDC 0555-9051-67

Published July 23, 2014 · Recall initiated: June 17, 2014

Summary

FDA records drug Class III recall D-1439-2014, published July 23, 2014 and initiated June 17, 2014. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 5265 blister packs; Lot: Lot 33805449A, Exp. 12/14. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: out of specification impurity test results.

What to do

Voluntary: Firm initiated · Letter

Get an email if VELIVET has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
VELIVET
Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide
Lot
Lot 33805449A, Exp. 12/14
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Velivet (desogestrel and ethinyl estradiol tablets - triphasic regimen), 0.1 mg/0.025 mg; 0.125 mg/0.025 mg; 0.15 mg/0.025 mg, 3 Dispensers x 28 Tablets, Barr Laboratories, Inc., Pomona, NY NDC 0555-9051-67 recalled?

Yes. FDA published recall D-1439-2014 on July 23, 2014. Reported hazard: Failed Impurities/Degradation Specifications: out of specification impurity test results.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: VELIVET.